Molecular beacon–based detection of circulating microRNA-containing extracellular vesicle as an α-synucleinopathy biomarker

Zhenwei Yu,Yuanchu Zheng,Huihui Cai,Siming Li,Genliang Liu,Wenyi Kou,Chen Yang,Shuangshuang Cao,Lei Chen,Xuedong Liu,Zhirong Wan,Ning Zhang,Xiaohong Li,Guiyun Cui,Ying Chang,Yue Huang,Hong Lv,Tao Feng
DOI: https://doi.org/10.1126/sciadv.adl6442
IF: 13.6
2024-05-17
Science Advances
Abstract:Early and precise diagnosis of α-synucleinopathies is challenging but critical. In this study, we developed a molecular beacon–based assay to evaluate microRNA-containing extracellular vesicles (EVs) in plasma. We recruited 1203 participants including healthy controls (HCs) and patients with isolated REM sleep behavior disorder (iRBD), α-synucleinopathies, or non–α-synucleinopathies from eight centers across China. Plasma miR-44438–containing EV levels were significantly increased in α-synucleinopathies, including those in the prodromal stage (e.g., iRBD), compared to both non–α-synucleinopathy patients and HCs. However, there are no significant differences between Parkinson's disease (PD) and multiple system atrophy. The miR-44438–containing EV levels negatively correlated with age and the Hoehn and Yahr stage of PD patients, suggesting a potential association with disease progression. Furthermore, a longitudinal analysis over 16.3 months demonstrated a significant decline in miR-44438–containing EV levels in patients with PD. These results highlight the potential of plasma miR-44438–containing EV as a biomarker for early detection and progress monitoring of α-synucleinopathies.
multidisciplinary sciences
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to develop a method for accurate and early diagnosis of α - synucleinopathies (such as Parkinson's disease, PD; multiple system atrophy, MSA). Specifically, the research team has developed a nano - flow cytometry detection method based on molecular beacons to evaluate the level of extracellular vesicles (EVs) containing microRNA - 44438 (miR - 44438) in plasma. This method aims to identify patients with α - synucleinopathies, especially those in the prodromal stage, such as patients with isolated rapid eye movement sleep behavior disorder (iRBD), by detecting these specific EVs, thereby achieving early diagnosis and progression monitoring of the disease. ### Main problem points: 1. **Challenges of early and accurate diagnosis**: Early and accurate diagnosis of α - synucleinopathies is very difficult because these diseases have complex symptoms and heterogeneity. Therefore, a simple and reliable method is needed for early diagnosis of these diseases. 2. **Exploration of biomarkers**: Existing biomarker detection methods have limitations, such as high cost and low sensitivity. Therefore, new detection techniques need to be developed to improve the accuracy and reliability of diagnosis. 3. **Identification of the prodromal stage**: iRBD is considered as the prodromal stage of α - synucleinopathies. Therefore, identifying biomarkers at this stage is crucial for early intervention. ### Research methods and results: - **Methods**: The research team used nano - cage molecular beacon (NCMB) probes, combined with nano - flow cytometry, to detect the level of miR - 44438 - containing EVs in plasma. - **Results**: - **Significant differences**: In patients with α - synucleinopathies (including PD and MSA patients), the level of plasma miR - 44438 - containing EVs was significantly higher than that in non - α - synucleinopathy patients and healthy control groups. - **Correlation with disease progression**: The level of miR - 44438 - containing EVs was negatively correlated with the patient's age, Hoehn and Yahr stage, indicating that it may be related to disease progression. - **Longitudinal study**: In the longitudinal cohort of PD patients, after 16.3 months of follow - up, it was found that the level of miR - 44438 - containing EVs decreased significantly, further supporting its potential as a disease - progression marker. - **Early diagnostic value**: In iRBD patients, the level of miR - 44438 - containing EVs was significantly higher than that in the healthy control group, indicating its potential value in prodromal - stage diagnosis. ### Conclusion: This study shows the application prospects of plasma miR - 44438 - containing EVs as a potential biomarker in the early diagnosis and progression monitoring of α - synucleinopathies. This finding provides important scientific basis and technical support for future clinical applications.